Aegis Now Offers Testing For Nearly 50 Different Synthetic Cannabinoids
NASHVILLE, Tenn. (December 15, 2014) – Aegis Sciences Corporation, one of the nation’s leading forensic toxicology and healthcare sciences laboratories, announced it has significantly expanded its testing profile of synthetic cannabinoids in blood specimens. This enhanced profile includes 46 synthetic cannabinoid compounds making it the most comprehensive analysis available for synthetic cannabinoids in post-mortem forensic toxicology.
“We are proud of this Aegis Research and Development effort and this new analytical method detects almost 20 more synthetic compounds than methods reported by other testing agencies and organizations in the United States,” said Aegis Founder, Chairman and CEO Dr. David L. Black.
Synthetic cannabinoids, also referred to as synthetic marijuana, and known by common brand names such as Spice or K2, are designed to affect the body in a manner similar to marijuana without including any organic substance derived from the marijuana plant.
According to The DAWN Report, an estimated 11,406 emergency department (ED) visits involved a synthetic cannabinoid. Three fourths of these ED visits involved patients aged 12 to 29 (75 percent), of which 78 percent were male.
In an attempt to keep up with the changing landscape of the illicit drug market, the 46 cannabinoids included in the analysis span across the variety of synthetic marijuana compounds and their multiple generation chemical structures.
About Aegis Sciences Corporation
Aegis Sciences Corporation is a toxicology laboratory specializing in forensic and healthcare services that provides science-driven testing and consulting for clients, such as professional and amateur sports organizations, leading college and university athletic programs, healthcare professionals, Fortune 500 companies, medical examiners, and government agencies throughout the United States.